1958 Company founded
1988 King-phar plant founded
1993 Advanced technology for manufacturing lyophilized powder imported from Germany, Spain and France
1995 Genetic engineering plant founded with a total surface area of 2,500 m²
1999 G-CSF was firstly launched in China. Qilu became one of the biggest supplier of antibiotic APIs in the world
2002 First inspection and approval by USFDA
2003 Changed from a State-owned to a private company
2006 Launched Permetrexed which extended the oncology portfolio. High-tech zone and Hainan manufacturing site founded
2008 Approved by MHRA (Medicine and Healthcare products Regulatory Administration of UK) for sterile API and by TGA (Therapeutic Goods Administration of Australia) for powder for injection and small volume parenteral solutions
2009 Qilu Drug Research Institute established and two additional sites founded in Neimenggu and Linyi.
2010 EDQM (European Directorate for the Quality of Medicines) approved 5 sterile products of Qilu Antibiotics
2011 Approved by FDA (US Food and Drug Administration) for sterile API and by Germany Authority for powder for injection
2013 Approved by FDA (US Food and Drug Administration) for powder for injection and Solid Oral Dosage
2014 Approved by AEMPS (Spanish Agency for Medicines and Health Products) for lyophilized powder for injection
2015 Approved by MHRA (Medicine and Healthcare products Regulatory Administration United Kindom) for powder for injection
